ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,598,684 | -68.1% | 279,981 | -63.9% | 0.00% | -50.0% |
| Q2 2023 | $23,850,305 | -45.5% | 775,872 | -36.2% | 0.00% | -60.0% |
| Q1 2023 | $43,789,205 | +79.2% | 1,215,354 | +96.5% | 0.01% | +66.7% |
| Q4 2022 | $24,440,749 | +1.7% | 618,440 | +3.4% | 0.01% | 0.0% |
| Q3 2022 | $24,030,000 | +7.4% | 598,061 | +12.3% | 0.01% | 0.0% |
| Q2 2022 | $22,384,000 | -66.5% | 532,445 | -68.9% | 0.01% | -57.1% |
| Q1 2022 | $66,744,000 | +418.9% | 1,713,133 | +430.7% | 0.01% | +366.7% |
| Q4 2021 | $12,863,000 | +48.1% | 322,781 | +34.3% | 0.00% | +50.0% |
| Q3 2021 | $8,687,000 | -68.8% | 240,379 | -64.6% | 0.00% | -66.7% |
| Q2 2021 | $27,834,000 | +101.2% | 679,051 | +114.1% | 0.01% | +100.0% |
| Q1 2021 | $13,836,000 | -53.1% | 317,205 | -46.2% | 0.00% | -62.5% |
| Q4 2020 | $29,497,000 | +514.4% | 589,341 | +416.3% | 0.01% | +700.0% |
| Q3 2020 | $4,801,000 | -89.5% | 114,149 | -87.9% | 0.00% | -93.8% |
| Q2 2020 | $45,729,000 | – | 941,905 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |